Medoba is the trade name for Dobasic Hydrazide Tablets, which can be taken at the same time as Pramipexole Hydrochloride Tablets. Dobasic hydrazide tablets are a combination preparation containing levodopa and benserazide, while pramipexole hydrochloride tablets are a single preparation. Both can be taken at the same time to adapt to the complex condition, enhance the therapeutic effect, and under the indications of pramipexole hydrochloride tablets, it is clearly proposed that it can be used in combination with levodopa. Therefore, the two drugs can be taken together. Dobasic hydrazide tablets are clinically used for the treatment of Parkinson’s disease, symptomatic Parkinson’s syndrome (post encephalitis, atherosclerotic or toxic), but not drug-induced Parkinson’s syndrome; pramipexole hydrochloride tablets are used for the treatment of the signs and symptoms of idiopathic Parkinson’s disease in adults, alone or in combination with levodopa. Adverse reactions such as agitation, anxiety, nausea, vomiting, diarrhea, and rash have been reported with Dobasic Acid Tablets; drowsiness, dizziness, dyskinesia, headache, nausea, insomnia, and fatigue have been reported with Pramipexole Hydrochloride Tablets. Dobasic hydrazide tablets are contraindicated in patients with endocrine diseases, renal impairment, hepatic impairment, cardiac diseases, psychiatric disorders, and angle-closure glaucoma; pramipexole hydrochloride tablets are contraindicated in patients who are allergic to the active ingredient of this product or any excipients. If you need to use dobasic hydrazide tablets and pramipexole hydrochloride tablets, you should use them under the guidance of a specialized physician, and should not use them on your own to avoid adverse reactions.